» Articles » PMID: 35337606

Clinical Metabolomics for Inborn Errors of Metabolism

Overview
Journal Adv Clin Chem
Specialty Biochemistry
Date 2022 Mar 26
PMID 35337606
Authors
Affiliations
Soon will be listed here.
Abstract

Metabolism is a highly regulated process that provides nutrients to cells and essential building blocks for the synthesis of protein, DNA and other macromolecules. In healthy biological systems, metabolism maintains a steady state in which the concentrations of metabolites are relatively constant yet are subject to metabolic demands and environmental stimuli. Rare genetic disorders, such as inborn errors of metabolism (IEM), cause defects in regulatory enzymes or proteins leading to metabolic pathway disruption and metabolite accumulation or deficiency. Traditionally, the laboratory diagnosis of IEMs has been limited to analytical methods that target specific metabolites such as amino acids and acyl carnitines. This approach is effective as a screening method for the most common IEM disorders but lacks the comprehensive coverage of metabolites that is necessary to identify rare disorders that present with nonspecific clinical symptoms. Fortunately, advancements in technology and data analytics has introduced a new field of study called metabolomics which has allowed scientists to perform comprehensive metabolite profiling of biological systems to provide insight into mechanism of action and gene function. Since metabolomics seeks to measure all small molecule metabolites in a biological specimen, it provides an innovative approach to evaluating disease in patients with rare genetic disorders. In this review we provide insight into the appropriate application of metabolomics in clinical settings. We discuss the advantages and limitations of the method and provide details related to the technology, data analytics and statistical modeling required for metabolomic profiling of patients with IEMs.

Citing Articles

Perspective: metabolomics has the potential to change the landscape of kidney transplantation diagnostics.

Kuypers D, Kamphorst J, de Loor H, ODay E Biomark Med. 2024; 18(17-18):787-794.

PMID: 39234983 PMC: 11457662. DOI: 10.1080/17520363.2024.2394383.


Olaris Global Panel (OGP): A Highly Accurate and Reproducible Triple Quadrupole Mass Spectrometry-Based Metabolomics Method for Clinical Biomarker Discovery.

Dorrani M, Zhao J, Bekhti N, Trimigno A, Min S, Ha J Metabolites. 2024; 14(5).

PMID: 38786757 PMC: 11123370. DOI: 10.3390/metabo14050280.


Metabolomics and lipidomics strategies in modern drug discovery and development.

Astarita G, Kelly R, Lasky-Su J Drug Discov Today. 2023; 28(10):103751.

PMID: 37640150 PMC: 10543515. DOI: 10.1016/j.drudis.2023.103751.


A Case Study of Dysfunctional Nicotinamide Metabolism in a 20-Year-Old Male.

DeBalsi K, Newman J, Sommerville L, Phillips 3rd J, Hamid R, Cogan J Metabolites. 2023; 13(3).

PMID: 36984839 PMC: 10055858. DOI: 10.3390/metabo13030399.